Drug-eluting stent

Global Drug-Eluting Stents Market (2020 to 2024) - Featuring Abbott, Biosensors International & Cook Medical Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, November 16, 2020

There has been remarkable growth in the development of coronary stents to avoid restenosis and thrombosis.

Key Points: 
  • There has been remarkable growth in the development of coronary stents to avoid restenosis and thrombosis.
  • Improvements include progress in the design and conformation of metallic or resorbable structures, with an adequate balance between trackability and radial force.
  • These developments led to growth in the drug-eluting stent market over the forecast period.
  • These phenomena are anticipated to fuel drug-eluting stents market growth over the forecast period.

VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting (CABG) Procedures in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Heart Association’s Virt

Retrieved on: 
Friday, November 13, 2020

These new analyses supported by Amarin were presented by Subodh Verma, M.D., Ph.D., FRCSC, Professor and Cardiac Surgeon at University of Toronto.

Key Points: 
  • These new analyses supported by Amarin were presented by Subodh Verma, M.D., Ph.D., FRCSC, Professor and Cardiac Surgeon at University of Toronto.
  • Coronary revascularization procedures, such as CABG, are invasive, carry multiple risks, and can have significant direct and indirect costs.
  • Patients with elevated triglycerides despite statin therapy have increased risk for ischemic events, including coronary revascularizations.
  • These procedures, whether pre-scheduled or performed in an emergency, inevitably result in additional time spent in a healthcare setting.

Implantable Drug Delivery Devices Market to Reach $13.21 Bn, Globally, by 2027 at 8.0% CAGR: Allied Market Research

Retrieved on: 
Wednesday, November 11, 2020

PORTLAND, Ore., Nov. 11, 2020 /PRNewswire/ -- Allied Market Research published a report, titled, " Implantable Drug Delivery Devices Market by Material (Silicon and Others), Product Type (Implantable Drug Eluting Stents, Implantable Contraceptive Drug Delivery Devices, Implantable Intraocular Drug Delivery Devices, Implantable Brachytherapy Seeds Devices, and Implantable Drug Delivery Pump Devices) and End User (Hospitals, Ambulatory Surgery Center, and Others): Global Opportunity Analysis and Industry Forecast, 2019-2027."

Key Points: 
  • PORTLAND, Ore., Nov. 11, 2020 /PRNewswire/ -- Allied Market Research published a report, titled, " Implantable Drug Delivery Devices Market by Material (Silicon and Others), Product Type (Implantable Drug Eluting Stents, Implantable Contraceptive Drug Delivery Devices, Implantable Intraocular Drug Delivery Devices, Implantable Brachytherapy Seeds Devices, and Implantable Drug Delivery Pump Devices) and End User (Hospitals, Ambulatory Surgery Center, and Others): Global Opportunity Analysis and Industry Forecast, 2019-2027."
  • According to the report, the global implantable drug delivery devices industry garnered $10.09 billion in 2019, and is projected to generate $13.21 billion by 2027, manifesting a CAGR of 8.0% from 2020 to 2027.
  • Download Detailed COVID-19 Impact Sample Report at: https://www.alliedmarketresearch.com/request-for-customization/449?reqfo...
    Surge in prevalence of chronic conditions, increase in demand for minimally invasive devices, and unwanted pregnancies propel the growth of the global implantable drug delivery devices market.
  • Manufacturing of implantable drug delivery devices has been stopped due to closure of factories with lockdown in many countries.

Implantable Drug Delivery Devices Market to Reach $13.21 Bn, Globally, by 2027 at 8.0% CAGR: Allied Market Research

Retrieved on: 
Wednesday, November 11, 2020

- Surge in prevalence of chronic conditions, increase in demand for minimally invasive devices, and unwanted pregnancies propel the growth of the global implantable drug delivery devices market.

Key Points: 
  • - Surge in prevalence of chronic conditions, increase in demand for minimally invasive devices, and unwanted pregnancies propel the growth of the global implantable drug delivery devices market.
  • PORTLAND, Ore., Nov. 11, 2020 /PRNewswire/ -- Allied Market Research published a report, titled, " Implantable Drug Delivery Devices Market by Material (Silicon and Others), Product Type (Implantable Drug Eluting Stents, Implantable Contraceptive Drug Delivery Devices, Implantable Intraocular Drug Delivery Devices, Implantable Brachytherapy Seeds Devices, and Implantable Drug Delivery Pump Devices) and End User (Hospitals, Ambulatory Surgery Center, and Others): Global Opportunity Analysis and Industry Forecast, 2019-2027."
  • Download Detailed COVID-19 Impact Sample Report at: https://www.alliedmarketresearch.com/request-for-customization/449?reqfo...
    Surge in prevalence of chronic conditions, increase in demand for minimally invasive devices, and unwanted pregnancies propel the growth of the global implantable drug delivery devices market.
  • Manufacturing of implantable drug delivery devices has been stopped due to closure of factories with lockdown in many countries.

Vascular Stents Markets Report 2020 - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017-2018 & 2019-2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 10, 2020

The "Vascular Stents Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vascular Stents Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • The report also provides the compound annual growth rate (CAGR) of the global vascular stents market for the forecast period 2019-2027.
  • How does the development of vascular stents provide scope of growth in the vascular stents market?
  • How is the evolving health care system in developing countries of Asia Pacific making an impact on the overall vascular stents market?

Global Drug-Eluting Stents Market

Retrieved on: 
Monday, November 9, 2020

The report also includes market projections through 2024 and the market rank for key market players.

Key Points: 
  • The report also includes market projections through 2024 and the market rank for key market players.
  • By product type, the market is segmented into polymer-based drug-eluting stents and polymer-free drug-eluting stents.By application, the market is segmented into coronary artery disease (CAD) and peripheral artery disease (PAD).
  • - Estimation of the market size and analyses of market trends, with data from 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2024
    - Market share analysis of the drug-eluting stents based on product, application, end-use, and region
    - Assessment of market dynamics for drug-eluting stents with market drivers and restraints explained, medical device regulations, market background and pipeline analysis of the stents
    - Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
    - Company profiles of the leading market players, including Abbott, B. Braun Melsungen AG, Biotronik SE & Co. KG, Boston Scientific Corp., Medtronic Plc and Cook Medical Inc.
  • The global market for drug-eluting stents was valued at REDACTED in 2018.The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach REDACTED by 2024.

Bioabsorbable Stents Market Research Report by Material, by Absorption Rate, by Application, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19

Retrieved on: 
Wednesday, November 4, 2020

NEW YORK, Nov. 4, 2020 /PRNewswire/ -- Bioabsorbable Stents Market Research Report by Material (Bioresorbable Metallic Stents and Bioresorbable Polymer-Based Stents), by Absorption Rate (Fast-Absorption Stents and Slow-Absorption Stents), by Application, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19

Key Points: 
  • NEW YORK, Nov. 4, 2020 /PRNewswire/ -- Bioabsorbable Stents Market Research Report by Material (Bioresorbable Metallic Stents and Bioresorbable Polymer-Based Stents), by Absorption Rate (Fast-Absorption Stents and Slow-Absorption Stents), by Application, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19
    This research report categorizes the Bioabsorbable Stents to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Material, the Bioabsorbable Stents Market studied across Bioresorbable Metallic Stents and Bioresorbable Polymer-Based Stents.
  • Based on Absorption Rate, the Bioabsorbable Stents Market studied across Fast-Absorption Stents and Slow-Absorption Stents.
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Bioabsorbable Stents Market during the forecast period?
  • What are the modes and strategic moves considered suitable for entering the Global Bioabsorbable Stents Market?

Global Bioabsorbable Stents Market Forecast 2020-2025 Featuring Key Players - Abbot Laboratories, Elixir Medical, Reva Medical, Kyoto Medical Planning - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 20, 2020

To overcome these roadblocks biodegradable stents came into existence in the recent years and is expected to considerably replace traditional stents.

Key Points: 
  • To overcome these roadblocks biodegradable stents came into existence in the recent years and is expected to considerably replace traditional stents.
  • The bioabsorbable stents market is classified on the basis of material used for manufacturing the products including polymeric and metallic.
  • Metal bioabsorbable stents are luring the medical device providers as they have the potential to perform similarly to stainless steel metal stents.
  • The key players in bioabsorbable stents market include:

OPTIMIZE Study Reports Lowest TLR Ever Achieved in an Investigational Device Exemption (IDE) Study With Svelte Medical System’s Bioresorbable Coated Drug-Eluting Coronary Stent

Retrieved on: 
Saturday, October 17, 2020

The Svelte Drug-Eluting Stent (DES) achieved 1.5% clinically-driven Target Lesion Revascularization (TLR) at 1 year, the lowest ever reported in an Investigational Device Exemption (IDE) clinical study.

Key Points: 
  • The Svelte Drug-Eluting Stent (DES) achieved 1.5% clinically-driven Target Lesion Revascularization (TLR) at 1 year, the lowest ever reported in an Investigational Device Exemption (IDE) clinical study.
  • The high TLF reported in both OPTIMIZE treatment groups is driven by the 25% of study subjects assessed peri-procedurally with high-sensitivity-troponin.
  • We are deeply grateful to each and every one of the patients, investigative team members and support personnel contributing to the OPTIMIZE study.
  • Headquartered in New Providence, New Jersey, Svelte Medical Systems ( www.sveltemedical.com ) is a privately-held company engaged in the development of highly deliverable balloon expandable stents.

Global Peripheral Stents Market Insights to 2024 - Players Include Abbott, Biotronik and Boston Medical Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, October 16, 2020

The "Global Peripheral Stents Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Peripheral Stents Market" report has been added to ResearchAndMarkets.com's offering.
  • This report was developed using extensive primary and secondary research by the publisher's analysts.
  • Data from proprietary databases, proprietary market reports, company reports, import/export databases, and secondary data sources on medical device markets were used to develop estimates of 2019 worldwide market size by product segment, ASPs, sales, and market share for the top suppliers by product segment.
  • Devices in this global market analysis include peripheral vascular stents, iliac artery stents, biliary stents, tracheobronchial stents.